---
title: "Glucotrack Merges With Lokahi Therapeutics; Former Holders to Own 90% Post-Conversion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292819350.md"
description: "Glucotrack merged with Lokahi Therapeutics, making Lokahi a subsidiary. Post-merger, Lokahi holders will own 90% of Glucotrack. To fund operations, Glucotrack raised ~$4.45 million via senior secured convertible notes and established a $50 million equity line with White Lion Capital. The company also granted security interests, obtained voting support, issued warrants, and signed registration rights agreements to ensure liquidity and listing compliance."
datetime: "2026-07-15T21:23:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292819350.md)
  - [en](https://longbridge.com/en/news/292819350.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292819350.md)
generator: "portal-rs"
---

# Glucotrack Merges With Lokahi Therapeutics; Former Holders to Own 90% Post-Conversion

Glucotrack closed a stock-for-stock merger with Lokahi Therapeutics, making Lokahi a wholly owned subsidiary and setting Lokahi's former holders to own 90% of Glucotrack on an as-converted, fully diluted basis after preferred conversion, with a 10% floor for existing holders. To fund operations and post-closing steps, Glucotrack completed a ~$4.45 million senior secured convertible bridge financing and granted first-lien security, obtained voting support for required approvals, and established a three-year equity line of up to $50 million with White Lion. The company also issued a five-year commitment warrant and entered a registration rights agreement to facilitate resale of ELOC-related securities. Management expects these actions to support liquidity, listing compliance and strategic execution following the merger.

**Agreement 1: Glucotrack Merges With Lokahi Therapeutics; Former Holders to Own 90% Post-Conversion**

-   **Agreement type**: Agreement and Plan of Merger
-   **Counterparty**: Lokahi Therapeutics
-   **Signed / Effective**: Jul 14 2026 / Jul 14 2026
-   **Duration / Termination**: One-time transaction
-   **Reason**: Combine businesses and realign capital structure

**Agreement 2: Glucotrack Raises ~$4.45 Million via Senior Secured Convertible Notes and Warrants**

-   **Agreement type**: Securities Purchase Agreement for senior secured convertible notes and warrants
-   **Counterparty**: Bridge Investors
-   **Signed / Effective**: Jul 14 2026 / Jul 14 2026
-   **Duration / Termination**: 9 months (notes)
-   **Reason**: Bridge liquidity during post-merger transition

**Agreement 3: Glucotrack Grants First-Lien Security to Back Bridge Notes**

-   **Agreement type**: Security Agreement securing bridge notes
-   **Counterparty**: White Lion Capital
-   **Signed / Effective**: Jul 14 2026 / Jul 14 2026
-   **Duration / Termination**: Until notes repaid
-   **Reason**: Secure obligations under bridge financing

**Agreement 4: Glucotrack Obtains Voting Support to Approve Bridge Issuances and Capital Actions**

-   **Agreement type**: Voting Support Agreement
-   **Counterparty**: White Lion Capital and Supporting Stockholders
-   **Signed / Effective**: Jul 14 2026 / Jul 14 2026
-   **Duration / Termination**: Until required approvals obtained
-   **Reason**: Facilitate approvals for financing and listing compliance

**Agreement 5: Glucotrack Secures Up to $50 Million Equity Line With White Lion**

-   **Agreement type**: Common Stock Purchase Agreement (Equity Line of Credit)
-   **Counterparty**: White Lion Capital
-   **Signed / Effective**: Jul 14 2026 / Jul 14 2026
-   **Duration / Termination**: 3 years
-   **Reason**: Flexible access to equity capital

**Agreement 6: Glucotrack Issues Five-Year Commitment Warrant as ELOC Consideration**

-   **Agreement type**: Commitment Warrant issuance
-   **Counterparty**: White Lion Capital
-   **Signed / Effective**: Jul 14 2026 / Jul 14 2026
-   **Duration / Termination**: 5 years
-   **Reason**: Compensate ELOC provider and align incentives

**Agreement 7: Glucotrack Grants Registration Rights for ELOC, Warrant and Related Shares**

-   **Agreement type**: Registration Rights Agreement
-   **Counterparty**: White Lion Capital
-   **Signed / Effective**: Jul 14 2026 / Jul 14 2026
-   **Duration / Termination**: Until resale registration obligations satisfied
-   **Reason**: Enable resale liquidity for issued securities

Original SEC Filing: Glucotrack, Inc. \[ GCTK \] - 8-K - Jul. 15, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [GCTK.US](https://longbridge.com/en/quote/GCTK.US.md)

## Related News & Research

- [GlucoTrack unit Lokahi Therapeutics expands ai2 Futures Lab collaboration with University of Georgia](https://longbridge.com/en/news/296614954.md)
- [GlucoTrack Shareholders Approve Key Governance and Capital Actions](https://longbridge.com/en/news/296385751.md)
- [GlucoTrack holds annual shareholder meeting with 36.1% of shares represented](https://longbridge.com/en/news/296360186.md)
- [Werewolf Therapeutics agrees to merge with Ambros Therapeutics in all-stock deal](https://longbridge.com/en/news/296615000.md)
- [BrainStorm Cell Therapeutics GAAP EPS of -$0.35](https://longbridge.com/en/news/296069988.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**